14 Mrz Cost & Coverage SYNTHROID® levothyroxine sodium tablets

Cost & Coverage SYNTHROID® levothyroxine sodium tablets

SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism. The health-eligible plans and/or PBMs listed here have not endorsed and are not affiliated with this AbbVie material. AbbVie is not responsible for the privacy policy, the content, or the accuracy of any websites accessed through a link on the SynthroidPro.com site. A link to other websites does not constitute an endorsement of AbbVie or the linked site, its products, or services.

• The Synthroid Delivers Program Brochure was developed for patients who want to learn more about the program.
• A link to other websites does not constitute an endorsement of AbbVie or the linked site, its products, or services.
• ‡Coverage requirements and benefit designs vary by payer and may change over time.
• Please be aware that coverage requirements vary by payer and change over time, so please consult with each payer directly for the most current coverage and reimbursement policies and determination processes.

SYNTHROID is covered* for 80% of patients with insurance in 202213†

The Synthroid Delivers Program Brochure was developed for patients who want to learn more about the program. For phone and fax prescriptions, ensure you have the patient’s latest contact number. The „optimal dose“ was determined for each patient as that dosage of thyroxine being taken when the thyrotropin-releasing hormone (TRH) response was normal (ie, an increase in TSH of between 4.7 and 25 mIU/L).

YOU CAN ALSO ENROLL PATIENTS INTO THE

Please be aware that coverage requirements vary by payer and change over time, so please consult with each payer directly for the most current coverage and reimbursement policies and determination processes. AbbVie does not guarantee that the use of any information provided here will result in coverage. The health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this material. Eligible health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this AbbVie material. HypothyroidismSYNTHROID® (levothyroxine sodium) tablets, for oral use is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

• In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
• For phone and fax prescriptions, ensure you have the patient’s latest contact number.
• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
• Eligible health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this AbbVie material.
• AbbVie is not responsible for the privacy policy, the content, or the accuracy of any websites accessed through a link on the SynthroidPro.com site.
• The health-eligible plans and/or PBMs listed here have not endorsed and are not affiliated with this AbbVie material.

SYNTHROID HAS EXTENSIVE COMMERCIAL INSURANCE COVERAGE12†

Voice your preference for SYNTHROID andobtain the patient’s approval to receive a text or call and confirm that their phone number is correct in the EMR. Voice your preference for SYNTHROID and obtain the patient’s approval to receive a text or call and confirm that their phone number is correct in the EMR.

KEY BENEFITS OF THE

Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. ‡Coverage requirements and benefit designs vary by payer and may change over time. The health plans and/or PBMs synthroid invention listed here have not endorsed and are not affiliated with this material. AbbVie is committed to helping appropriate patients obtain access to SYNTHROID by providing reimbursement and access information.